Thermo Fisher Profit Up, Warns of Inflation from Iran War — Update

By Nicholas G. Miller

Thermo Fisher Scientific posted higher first-quarter profit and revenue and raised its full-year guidance to incorporate a recent acquisition, but warned of inflation from the war in the Middle East.

Chief Executive Marc Casper said there is added complexity in the macroeconomic environment given the Iran conflict. "We expect this to create some modest level of inflationary pressure," he said.

The company also said it was facing headwinds due to weak demand for instruments from academic and government customers in the U.S. and China. Thermo Fisher's analytical instruments segment saw reported revenue flat from the previous year, while organic revenue declined 2%.

Shares fell 7.1% to $477.48 in premarket trading.

For the first quarter, the company reported net income of $1.65 billion, or $4.43 a share, up from $1.51 billion, or $3.98 a share, the year prior.

Adjusted earnings were $5.44 a share. Analysts polled by FactSet had expected $5.25 a share.

Revenue rose 6% to $11.01 billion. Wall Street had expected $10.86 billion. Organic revenue growth was 1%.

Last month, the company completed its $8.88 billion acquisition of Clario, a provider of data solutions for clinical trials.

On Thursday, Thermo Fisher raised its full-year guidance to incorporate the Clario acquisition. It now expects revenue of $47.3 billion to $48.1 billion, up from its previous estimate of $46.3 billion to $47.2 billion. It also forecast adjusted earnings of $24.64 to $25.12 a share, up from its prior guidance of $24.22 to $24.80 a share.

Analysts see full-year revenue of $47.09 billion and adjusted earnings of $24.66 a share.

Write to Nicholas G. Miller at nicholas.miller@wsj.com

(END) Dow Jones Newswires

April 23, 2026 09:56 ET (13:56 GMT)